Insider Transactions Reported by 19 Insiders of Athenex, Inc.

Location: Buffalo, NY

Key facts

Athenex, Inc. has 19 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are not currently available.

Change

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 May 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Athenex, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Johnson Yiu Nam Lau	CEO and Chairman of the Board, Director	$405,210	Mixed	05 May 2023
Jeffrey Yordon	COO, and President, Athenex Pharmaceutical Division.	$334,482	Mixed	03 Aug 2022
Manson Fok	Director	$203,972	Mixed	21 Apr 2023
William Wei Zuo	President, China Division	$194,321	Mixed	03 Aug 2021
Daniel Lang	Pres Cell Therapy, VP Corp Dev	$110,962	Mixed	16 Sep 2022
Rudolf Kwan	EVP, Chief Medical Officer	$67,750	Mixed	05 May 2023
Jinn Wu	Director	$47,331	Mixed	21 Apr 2023
Jordan Kanfer	Director	$23,237	Mixed	03 Aug 2022
Benson Kwan Hung Tsang	Director	$23,011	Mixed	21 Apr 2023
John Vierling	Director	$16,767	Mixed	21 Apr 2023
Kim Campbell	Director	$13,600	Mixed	03 Aug 2021
Stephanie A. Davis	Director	$10,900	Mixed	21 Apr 2023
Simon Pedder	Officer	$7,222	Mixed	03 Aug 2021
Michael Smolinski	Chief Scientific Officer	$7,035	Mixed	16 Nov 2021
Robert J. Spiegel	Director	$6,245	Mixed	21 Apr 2023
Timothy DeVere Cook	Chief Business and Commercial Officer, Proprietary Drugs	$5,630	Mixed	05 May 2023
Joe Annoni	Chief Financial Officer	$510	Mixed	22 Feb 2023
Steven J. Adams	Interim Chief Acct Officer		Mixed	03 Aug 2021
Teresa Brophy Bair	General Counsel, SVP Admin.		Mixed	03 Aug 2021

Top shareholders of Athenex, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Johnson Yiu Nam Lau	3/4/5	CEO and Chairman of the Board, Director	— mixed-class rows	318,819 mixed-class rows	$405,210	—	05 May 2023	3/4/5
Jeffrey Yordon	3/4/5	COO, and President, Athenex Pharmaceutical Division.	— mixed-class rows	433,443 mixed-class rows	$334,482	—	03 Aug 2022	3/4/5
Manson Fok	3/4/5	Director	— mixed-class rows	153,350 mixed-class rows	$203,972	—	21 Apr 2023	3/4/5
William Wei Zuo	3/4/5	President, China Division	— mixed-class rows	167,883 mixed-class rows	$194,321	—	03 Aug 2021	3/4/5
Daniel Lang	3/4/5	Pres Cell Therapy, VP Corp Dev	— mixed-class rows	319,090 mixed-class rows	$110,962	—	16 Sep 2022	3/4/5
Rudolf Kwan	3/4/5	EVP, Chief Medical Officer	— mixed-class rows	56,191 mixed-class rows	$67,750	—	05 May 2023	3/4/5
Jinn Wu	3/4/5	Director	— mixed-class rows	35,552 mixed-class rows	$47,331	—	21 Apr 2023	3/4/5
Jordan Kanfer	3/4/5	Director	— mixed-class rows	34,586 mixed-class rows	$23,237	—	03 Aug 2022	3/4/5
Benson Kwan Hung Tsang	3/4/5	Director	— mixed-class rows	17,920 mixed-class rows	$23,011	—	21 Apr 2023	3/4/5
John Vierling	3/4/5	Director	— mixed-class rows	13,204 mixed-class rows	$16,767	—	21 Apr 2023	3/4/5
Kim Campbell	3/4/5	Director	— mixed-class rows	25,000 mixed-class rows	$13,600	—	03 Aug 2021	3/4/5
Stephanie A. Davis	3/4/5	Director	— mixed-class rows	8,890 mixed-class rows	$10,900	—	21 Apr 2023	3/4/5
Simon Pedder	3/4/5	Officer	— mixed-class rows	65,310 mixed-class rows	$7,222	—	03 Aug 2021	3/4/5
Michael Smolinski	3/4/5	Chief Scientific Officer	— mixed-class rows	55,173 mixed-class rows	$7,035	—	16 Nov 2021	3/4/5
Robert J. Spiegel	3/4/5	Director	— mixed-class rows	5,467 mixed-class rows	$6,245	—	21 Apr 2023	3/4/5
Timothy DeVere Cook	3/4/5	Chief Business and Commercial Officer, Proprietary Drugs	— mixed-class rows	8,228 mixed-class rows	$5,630	—	05 May 2023	3/4/5
Joe Annoni	3/4/5	Chief Financial Officer	— mixed-class rows	7,250 mixed-class rows	$510	—	22 Feb 2023	3/4/5
Teresa Brophy Bair	3/4/5	General Counsel, SVP Admin.	— mixed-class rows	75,000 mixed-class rows	—	—	03 Aug 2021	3/4/5
Steven J. Adams	3/4/5	Interim Chief Acct Officer	— mixed-class rows	55,000 mixed-class rows	—	—	03 Aug 2021	3/4/5

Recent Insider Transactions by Companies or Individuals for Athenex, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.